What is Zacks Research's Forecast for JAZZ Q2 Earnings?

Key Points

• Zacks Research raised its Q2 2026 EPS estimate for Jazz Pharmaceuticals to $5.24 from $4.68, signaling higher expectations for the upcoming quarter.
• The firm also lifted forecasts across multiple future periods, including FY2026 EPS to $21.72 and FY2027 EPS to $22.26, suggesting a more optimistic longer-term earnings outlook.
• Broader analyst sentiment remains favorable, with several firms maintaining or raising bullish ratings and price targets; MarketBeat shows a consensus rating of “Moderate Buy” and an average target price of $242.65.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) - Zacks Research boosted their Q2 2026 EPS estimates for shares of Jazz Pharmaceuticals in a report issued on Tuesday, May 26th. Zacks Research analyst Team now anticipates that the specialty pharmaceutical company will post earnings per share of $5.24 for the quarter, up from their previous forecast of $4.68. The consensus estimate for Jazz Pharmaceuticals' current full-year earnings is $20.75 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals' Q3 2026 earnings at $5.49 EPS, Q4 2026 earnings at $5.64 EPS, FY2026 earnings at $21.72 EPS, Q1 2027 earnings at $4.58 EPS, Q2 2027 earnings at $5.54 EPS, Q3 2027 earnings at $5.92 EPS, Q4 2027 earnings at $6.22 EPS, FY2027 earnings at $22.26 EPS, Q1 2028 earnings at $5.13 EPS and FY2028 earnings at $22.77 EPS.

JAZZ has been the topic of several other reports. Barclays raised their target price on shares of Jazz Pharmaceuticals from $234.00 to $253.00 and gave the stock an "overweight" rating in a research report on Wednesday. Leerink Partners raised their target price on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 22nd. Bank of America raised their target price on shares of Jazz Pharmaceuticals from $263.00 to $275.00 and gave the stock a "buy" rating in a research report on Wednesday, February 25th. Morgan Stanley reissued an "overweight" rating and issued a $245.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, May 7th. Finally, Piper Sandler raised their target price on shares of Jazz Pharmaceuticals from $232.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $242.65.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $235.38 on Friday. Jazz Pharmaceuticals has a 12-month low of $105.00 and a 12-month high of $243.32. The stock has a market capitalization of $14.77 billion, a P/E ratio of -11,763.12, a P/E/G ratio of 0.42 and a beta of 0.27. The firm's 50-day moving average is $206.99 and its two-hundred day moving average is $183.17. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The company had revenue of $1.07 billion for the quarter.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP increased its stake in shares of Jazz Pharmaceuticals by 11.8% in the third quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company's stock worth $373,855,000 after buying an additional 298,815 shares during the last quarter. Ruffer LLP bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth $2,425,000. Essex Investment Management Co. LLC bought a new stake in shares of Jazz Pharmaceuticals in the third quarter worth $2,697,000. JPMorgan Chase & Co. increased its stake in shares of Jazz Pharmaceuticals by 8.5% in the third quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company's stock worth $246,092,000 after buying an additional 145,865 shares during the last quarter. Finally, Iron Triangle Partners LP bought a new stake in shares of Jazz Pharmaceuticals in the third quarter worth $19,770,000. Hedge funds and other institutional investors own 89.14% of the company's stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $190.50, for a total value of $1,143,000.00. Following the transaction, the director owned 384,682 shares in the company, valued at approximately $73,281,921. This trade represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Heather Ann Mcsharry sold 2,000 shares of the firm's stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $241.00, for a total transaction of $482,000.00. Following the completion of the transaction, the director owned 18,449 shares in the company, valued at $4,446,209. The trade was a 9.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 12,028 shares of company stock worth $2,522,587. 4.30% of the stock is currently owned by corporate insiders.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Zacks Research raised its earnings outlook across several periods for Jazz Pharmaceuticals, including FY2026, FY2027, FY2028 and multiple quarterly estimates, reinforcing a stronger long-term profit picture for JAZZ.
• Positive Sentiment: Jazz Pharmaceuticals also received upbeat analyst support more broadly, with firms such as UBS, RBC and TD Cowen previously lifting price targets and/or ratings, which can add to investor confidence in the stock.
• Positive Sentiment: The company reported encouraging clinical-news momentum after publishing Phase 3 HERIZON-GEA-01 results in The New England Journal of Medicine, highlighting durable survival benefits for Ziihera combinations in HER2-positive gastroesophageal cancer. Article Title
• Neutral Sentiment: Insider selling by directors Heather Ann Mcsharry and Rick E. Winningham may temper enthusiasm a bit, but the sales were relatively small versus their holdings and do not by themselves change the core investment story.
• Neutral Sentiment: Recent short-interest data was not meaningful, showing effectively zero reported short interest, so it does not appear to be a major near-term trading factor for Jazz Pharmaceuticals.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.